Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.17B P/E - EPS this Y -158.50% Ern Qtrly Grth -
Income -167.82M Forward P/E -42.22 EPS next Y 28.30% 50D Avg Chg 2.00%
Sales 289.21M PEG 0.36 EPS past 5Y 67.92% 200D Avg Chg 13.00%
Dividend N/A Price/Book 0.92 EPS next 5Y -52.25% 52W High Chg -40.00%
Recommedations 2.70 Quick Ratio 6.60 Shares Outstanding 29.90M 52W Low Chg 39.00%
Insider Own 32.58% ROA -3.47% Shares Float 19.89M Beta 1.42
Inst Own 49.01% ROE -14.58% Shares Shorted/Prior 625.35K/611.22K Price 39.26
Gross Margin 36.12% Profit Margin -58.03% Avg. Volume 205,009 Target Price 26.67
Oper. Margin -47.50% Earnings Date May 3 Volume 194,782 Change 1.11%
About Fulgent Genetics, Inc.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Fulgent Genetics, Inc. News
04/11/24 Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
04/11/24 Fulgent Genetics (NASDAQ:FLGT) shareholders have earned a 26% CAGR over the last five years
03/01/24 An Intrinsic Calculation For Fulgent Genetics, Inc. (NASDAQ:FLGT) Suggests It's 32% Undervalued
03/01/24 Fulgent Genetics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
02/29/24 Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call Transcript
02/28/24 Q4 2023 Fulgent Genetics Inc Earnings Call
02/28/24 Fulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023
02/28/24 Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
02/13/24 Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
02/09/24 Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
11/25/23 The 3 Best Digital Health Stocks for Personalized Medicine
11/14/23 Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
11/05/23 Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript
11/03/23 Q3 2023 Fulgent Genetics Inc Earnings Call
11/03/23 Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
11/03/23 Fulgent Genetics Inc (FLGT) Reports Q3 2023 Financial Results
11/03/23 Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates
11/03/23 Fulgent Reports Third Quarter 2023 Financial Results
11/01/23 Fulgent Genetics, Inc. (NASDAQ:FLGT) is definitely on the radar of institutional investors who own 47% of the company
10/30/23 Top 20 Genomics Companies in the World
FLGT Chatroom

User Image Leela1209 Posted - 8 hours ago

$FLGT the Executive Team needs to buy some shares before ER…. Show us that you believe and I will buy more!!! Small good faith goes a long way!!

User Image Leela1209 Posted - 1 day ago

$FLGT Let’s let the run begin for the earnings next week!!

User Image CrayP Posted - 1 day ago

$FLGT Even using the sale of $NVTAQ's distressed assets out of bankruptcy at 1X Sales would value $FLGT at $35 per share (including net cash). That's a minimum 40% Ming discount! Stop destroying value and sell the company to $LABC, $NEO or $DGX and use your proceeds to do whatever you want at your expense instead of the expense of shareholders! This company is not your personal piggy bank and the board has a fiduciary duty to all shareholders and not the largest.

User Image UncleStock Posted - 1 day ago

$SMLR $FLGT $IRMD $QDEL suggested for Medical Equipment and Services - value screen: https://zpr.io/58kdvfpRwWhn

User Image Leela1209 Posted - 3 days ago

$FLGT LET THE PARTY BEGIN FROM HERE THRU EARNINGS AND THEN MOMENTUM KICKS IN🤮🤮💰💰

User Image Endergast07 Posted - 1 week ago

$FLGT https://www.ft.com/content/76aceb49-a32e-43e1-89f4-88b7ffb713c9 Ming in China with Xi Jinping

User Image ClarityOfPurpose Posted - 1 week ago

$FLGT They repurchased almost a million shares in 2023. Sounds like a lot - but only a small $25M amount was involved. Time to ramp that repurchasing effort up, Paul! Just tell Ming that you are working on a ‘special project’.

User Image ClarityOfPurpose Posted - 1 week ago

$FLGT So tell me again, why didn’t the executives sell more shares when the price was $180? Makes me not feel so bad.

User Image ClarityOfPurpose Posted - 1 week ago

$FLGT I got me some of them ‘under $20’ shares that Sexydream has been touting for months and years. Yippee- I think 🤔

User Image ClarityOfPurpose Posted - 1 week ago

$FLGT Update to CT gov posted today. Phase 2 study started one week ago, on April 10. Study will run through 2025. https://classic.clinicaltrials.gov/ct2/show/NCT06332092

User Image Endergast07 Posted - 1 week ago

$FLGT Hmm, I guess I should really not have bought all those 17.5 Calls for April 19th, and July, half a year ago, when the price was at 27. Now I have even more shares of FLGT..., brutal...

User Image ClarityOfPurpose Posted - 1 week ago

$FLGT If it dips below 20 tomorrow, I probably buy some more. Just because Ming owns a whole lot more long shares, which are separate from his underlying share investments in these variable forward agreements. He’s a smart man who eventually should make the right business decisions for shareholders regarding the pharma business. Especially the largest personal shareholder (himself).

User Image CrayP Posted - 1 week ago

$FLGT Ming, your legacy of attempting to build an oncology company has resulted in board resignations, breach of fiduciary duty and value destruction. Stick to your competencies, which do not lie in drug development.

User Image ClarityOfPurpose Posted - 1 week ago

$FLGT Do we break below $20 pps and $600M market cap tomorrow? A less financially conflicted CEO, one without prepaid forward agreements, would let his CFO buy back a whole lot of shares right now.

User Image Ernst_Grafenberg Posted - 1 week ago

$FLGT no debt, lots of cash. Interest rates don't matter for this company

User Image ClarityOfPurpose Posted - 1 week ago

$FLGT Prepaid variable forward agreements have been good for Ming but not for regular shareholders. It’s almost like Ming was buying puts on his company. Shameful.

User Image Stock_Titan Posted - 2 weeks ago

$FLGT Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024 https://www.stocktitan.net/news/FLGT/fulgent-genetics-to-announce-first-quarter-2024-financial-results-on-msvespv6s08c.html

User Image bigtuna7 Posted - 2 weeks ago

Inverse H&S setups all over bios $XBI $CRSP $FLGT $BCYC

User Image wavw Posted - 2 weeks ago

$FLGT any upcoming catalyst

User Image bigtuna7 Posted - 3 weeks ago

$FLGT $BCYC Took some

User Image jf152 Posted - 3 weeks ago

@ClarityOfPurpose @Sexydream this is my take as well... There's literally no downside to the pharma side UNLESS he burns the whole company to the ground funding it all the way until a futile conclusion. And I just don't see Ming doing that. Money is EXPENSIVE right now. The Pharma side is 1.) being saved from having to lend money and 2.) $FLGT is making a nice piece of change on their current assets.

User Image Ernst_Grafenberg Posted - 3 weeks ago

$FLGT Ming needs to find an AI company to acquire that can strengthen FLGT genetic products

User Image Sexydream Posted - 3 weeks ago

$FLGT ming = FRAUD. Told yall to short this trash!

User Image ClarityOfPurpose Posted - 3 weeks ago

$FLGT This is beautiful. Ming cut another great prepaid variable forward agreement deal for himself by getting an additional $17M more to terminate the older share delivery timing and then rewrite and extend the forward agreement to end on March 2027. The banker from the earlier deal is probably too embarrassed to terminate in 2025 in my opinion. Wants to keep his job for two more years. 😉 https://ir.fulgentgenetics.com/static-files/6572fb0f-21b0-4c7d-aa38-ee3dd39e1ef1

User Image CrayP Posted - 3 weeks ago

$FLGT MMMIIIIIIINNNNNNGGGGG!!!!!!!

User Image ClarityOfPurpose Posted - 3 weeks ago

$FLGT On 6/8/22, one of Ming’s derivative deals gave him $44M up front for ceding 1M shares total, involving eight transactions in April 2025. A very good deal indeed. Ming knows he can buy back those shares for his trust at less than half the price. He knew what he was doing. The bank and existing shareholders in 2022 got snookered to some degree. https://ir.fulgentgenetics.com/static-files/78d8bd30-c7ee-4dc8-a0a6-5fce8283ee9d

User Image ClarityOfPurpose Posted - 3 weeks ago

$FLGT A CEO would typically want to buy back a huge amount of shares right now with all these cash equivalents that are on hand. But remember that Ming had cut a couple of odd derivative transactions for his personal ownership/trust shares a while back that would cap his upside price profit, but more importantly, put a floor under his share price value to be in the upper 20s. I think those derivative deals last until 2026, if I recall correctly. The bank doing the deal got suckered in my opinion. Ming can probably just cash those derivatives in the high 20s at some point and buy shares on the open market for much less.

User Image Mottdahopple Posted - 3 weeks ago

$FLGT lower lows lower highs standing down

User Image Sexydream Posted - 3 weeks ago

$FLGT CRACKED into the 20s. How long before we get into the teens and where is the bottom? I think teens in 3 weeks, bottom may be 15-17 a share depending on how severe the recession is next yr.

User Image Leela1209 Posted - 3 weeks ago

$FLGT MING CAN YOU LEARN FROM YOUR MISTAKES AND REMAKE BETTER DECISIONS GOING FORWARD. You sure HAVE THE EXPERIENCE AND WISDOM LETS FOCUS ON PROFITABILITY AS GROWTH AND INVESTMENTS CAN DERAIL YOU. So just focus on making profitable sales and pause the rest of the SHIT PLEASE:)

Analyst Ratings
Piper Sandler Neutral Mar 6, 24
UBS Neutral Dec 7, 23
Piper Sandler Neutral Oct 16, 23
Credit Suisse Outperform Mar 2, 23
Piper Sandler Neutral Dec 8, 22
Raymond James Outperform Nov 18, 22
Credit Suisse Outperform Nov 14, 22
Piper Sandler Overweight Nov 14, 22
Credit Suisse Outperform Aug 25, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Xie Jian President and COO President and COO Dec 11 Sell 26.5 22,000 583,000 363,124 12/13/23
Xie Jian President and COO President and COO Dec 04 Sell 27.5732 1,779 49,053 385,124 12/06/23
Kim Paul CFO and Treasurer CFO and Treasurer Dec 04 Sell 27.5732 1,437 39,623 200,460 12/06/23
Gao Hanlin Chief Scientific Off.. Chief Scientific Officer Dec 04 Sell 27.5732 1,437 39,623 905,882 12/06/23
Xie Jian President and COO President and COO Nov 16 Sell 27.2511 1,617 44,065 386,903 11/20/23
Kim Paul CFO and Treasurer CFO and Treasurer Nov 16 Sell 27.2511 1,307 35,617 201,897 11/20/23
Xie Jian President and COO President and COO Sep 07 Sell 31.4079 1,492 46,861 416,022 09/11/23
Kim Paul CFO and Treasurer CFO and Treasurer Sep 07 Sell 31.4079 1,492 46,861 214,061 09/11/23
Kim Paul CFO and Treasurer CFO and Treasurer Aug 28 Sell 33.6243 10,299 346,297 215,553 08/30/23
Xie Jian President and COO President and COO Jun 02 Sell 40.2961 1,433 57,744 425,794 06/06/23
Kim Paul CFO and Treasurer CFO and Treasurer Jun 02 Sell 40.2961 1,403 56,535 228,890 06/06/23
Gao Hanlin Chief Scientific Off.. Chief Scientific Officer Jun 02 Sell 40.2961 1,000 40,296 914,391 06/06/23
Xie Jian President and COO President and COO Nov 30 Sell 34.3932 685 23,559 430,074 12/02/22
KIM PAUL CFO and Treasurer CFO and Treasurer Sep 06 Sell 41.3942 662 27,403 149,507 09/08/22
Xie Jian President and COO President and COO Aug 30 Sell 44.183 675 29,824 309,729 09/01/22
Xie Jian President and COO President and COO Aug 17 Sell 48.8945 1,414 69,137 310,404 08/19/22
KIM PAUL CFO and Treasurer CFO and Treasurer Aug 17 Sell 48.8945 1,945 95,100 150,169 08/19/22
Gao Hanlin Chief Scientific Off.. Chief Scientific Officer Aug 17 Sell 48.8945 370 18,091 855,280 08/19/22
KIM PAUL CFO and Treasurer CFO and Treasurer Jun 02 Sell 55.102 415 22,867 153,162 06/06/22
KIM PAUL CFO and Treasurer CFO and Treasurer Mar 03 Sell 56.3081 454 25,564 155,574 03/04/22
KIM PAUL CFO and Treasurer CFO and Treasurer Nov 16 Sell 96.16 2,169 208,571 131,826 11/18/21
KIM PAUL CFO and Treasurer CFO and Treasurer Jun 04 Sell 72.8 1,250 91,000 142,188 06/04/21
KIM PAUL CFO and Treasurer CFO and Treasurer May 27 Sell 72.92 28,358 2,067,865 143,438 05/27/21
Xie Jian Chief Operating Offi.. Chief Operating Officer May 20 Sell 72.6 1,931 140,191 340,041 05/20/21